The next breakthrough in human health won’t come from a hospital. It will come from a platform. We back both.
We invest where clinical AI, genomic intelligence, and diagnostic platforms converge — backing the companies that become the substrate precision health runs on.
AI systems that augment physician judgment — from diagnostic imaging to treatment planning — compressing clinical decisions from days to seconds with better outcomes.
Next-generation sequencing, multi-omics platforms, and pharmacogenomic systems that match patients to therapies based on their molecular profile, not population averages.
EHR modernization, interoperability platforms, and clinical data pipelines that transform fragmented health data into actionable intelligence for providers.
AI-driven target identification, molecule design, and clinical trial optimization that compress drug development timelines from decades to years.
Computer vision and NLP systems that detect cancers, cardiac conditions, and neurological disorders from imaging and clinical notes with superhuman accuracy.
Whole-genome sequencing platforms and polygenic risk scoring that enable personalized treatment selection based on individual molecular profiles.
Continuous biosensor networks and wearable platforms that detect clinical deterioration hours before symptoms manifest — reducing hospital readmissions by 40%.
AI-driven molecule design, target identification, and virtual screening platforms that compress preclinical discovery timelines from years to months.
Ambient documentation, automated coding, and decision-support systems that give physicians back 3 hours per day currently lost to administrative burden.
AI-powered therapy, digital phenotyping, and continuous mood monitoring systems that scale access to mental health support beyond the limits of human providers.
Build systems that detect disease earlier, classify conditions more accurately, and match patients to optimal treatments — faster than any human physician.
Free clinical data from proprietary silos, enabling researchers, providers, and patients to access complete health records across every care setting.
Deploy AI-powered health infrastructure that brings world-class diagnostic and therapeutic capabilities to underserved populations globally.
Compress the drug discovery pipeline from decades to years, reducing the cost and time required to bring life-saving therapies to patients who need them.
Diagnostic imaging, NLP for clinical notes, predictive analytics, and clinical decision-support tools.
Sequencing platforms, multi-omics integration, biomarker discovery, and pharmacogenomic systems.
Telemedicine, remote monitoring, digital therapeutics, and patient engagement platforms.
EHR interoperability, FHIR APIs, clinical data warehouses, and health information exchanges.
AI-driven drug design, virtual screening, clinical trial optimization, and regulatory automation.
Smart surgical instruments, implantable sensors, robotic surgery platforms, and point-of-care devices.
Health care is not a sector we watch — it is the imperative we were built to fund. Every generation produces a handful of platforms that become permanent clinical infrastructure. Antibiotics were the last one. Precision medicine is this one.
We invest in founders building the diagnostic and therapeutic layer of the global economy. We look for companies that own proprietary data advantages, build moats through clinical validation, and understand that regulatory clearance is the ultimate moat.
Our edge: we evaluate clinical evidence, not pitch decks. We invest in companies we’ve validated alongside. And we go deep in the conditions that matter most.
Great products are not built in isolation. We offer structured guidance through each phase of development — from early validation to scaling — so founders can move with clarity and confidence.
We help you validate assumptions fast — through user interviews, lightweight prototypes, and rapid feedback loops before a single line of production code is written.
We guide technical architecture decisions and build prioritized roadmaps that balance speed-to-market with long-term scalability and maintainability.
Two-week cycles of build, measure, learn. We embed alongside your team to ship features that matter — not endless backlogs that never see production.
Once product-market fit is locked, we help you scale infrastructure, optimize performance, and prepare your stack for the inflection point every great company hits.
We made a simple rule, never promise what we can't deliver. Then we deliver more than we promise.
Ideas are easy. Principles are hard. We back founders with the resolve to see something through.
The traditional model takes. We give. Every interaction should leave a founder stronger than before.
Building something lasting takes patience. We're here to walk that path with you.
We don't move fast. We move right.
We know who we
are. We know who we back.
We invest in the thesis before the market writes it.
The layer below the application — models, data pipelines, compute. The picks and shovels of the AI era.
Nations are rearming. The companies building the next generation of autonomous systems, propulsion, and defense platforms will define the next century.
AI-powered diagnostics, early detection, and personalized medicine. The trillion-dollar transformation of how humanity treats disease.
Reimagining the rails for the next generation of capital markets, payments, and financial intelligence.


























